Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;173(3):588-600.
doi: 10.1111/bph.13390. Epub 2016 Jan 13.

Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222

Affiliations

Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222

Maarten L J Doornbos et al. Br J Pharmacol. 2016 Feb.

Abstract

Background and purpose: Allosteric modulation of the mGlu2 receptor is a potential strategy for treatment of various neurological and psychiatric disorders. Here, we describe the in vitro characterization of the mGlu2 positive allosteric modulator (PAM) JNJ-46281222 and its radiolabelled counterpart [(3) H]-JNJ-46281222. Using this novel tool, we also describe the allosteric effect of orthosteric glutamate binding and the presence of a bound G protein on PAM binding and use computational approaches to further investigate the binding mode.

Experimental approach: We have used radioligand binding studies, functional assays, site-directed mutagenesis, homology modelling and molecular dynamics to study the binding of JNJ-46281222.

Key results: JNJ-46281222 is an mGlu2 -selective, highly potent PAM with nanomolar affinity (KD = 1.7 nM). Binding of [(3) H]-JNJ-46281222 was increased by the presence of glutamate and greatly reduced by the presence of GTP, indicating the preference for a G protein bound state of the receptor for PAM binding. Its allosteric binding site was visualized and analysed by a computational docking and molecular dynamics study. The simulations revealed amino acid movements in regions expected to be important for activation. The binding mode was supported by [(3) H]-JNJ-46281222 binding experiments on mutant receptors.

Conclusion and implications: Our results obtained with JNJ-46281222 in unlabelled and tritiated form further contribute to our understanding of mGlu2 allosteric modulation. The computational simulations and mutagenesis provide a plausible binding mode with indications of how the ligand permits allosteric activation. This study is therefore of interest for mGlu2 and class C receptor drug discovery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structure of JNJ‐46281222. The position of the tritium label in [3H]‐JNJ‐46281222 is denoted by *.
Figure 2
Figure 2
Characterization of [3H]‐JNJ‐46281222 binding to mGlu2 receptors stably expressed at CHO‐K1 membranes. (A) Saturation analysis of [3H]‐JNJ‐46281222 binding. A representative experiment is shown with similar data being obtained in two additional experiments. (B) Association and dissociation kinetics of 6 nM [3H]‐JNJ‐46281222 at the mGlu2 receptor at 15°C. Association data were best fitted using a one‐phase exponential association model, whereas data for dissociation curves were best fitted using a two‐phase exponential decay model. Data are expressed as percentage of specific [3H]‐JNJ‐46281222 binding and are shown as mean ± SEM of at least four individual experiments. Where bars are not shown, SEM values are within the symbol.
Figure 3
Figure 3
The effects of glutamate and GTP on [3H]‐JNJ‐46281222 binding. (A) Increasing concentrations of glutamate enhance the specific binding of 6 nM [3H]‐JNJ‐46281222 to mGlu2 receptors expressed at CHO‐K1 cell membranes, whereas GTP inhibits specific [3H]‐JNJ‐46281222 binding. (B) Effects of glutamate and GTP on homologous displacement of [3H]‐JNJ‐46281222 from mGlu2 receptors expressed at CHO‐K1 membranes. Data are normalized to specific binding in the absence of glutamate or GTP (set at 100%). (C, D) The effect of glutamate on mGlu2 receptor association and dissociation of [3H]‐JNJ‐46281222. Data are expressed as specific binding of the respective curve, association plateaus are fixed at 100% specific [3H]‐JNJ‐46281222 binding and dissociation plateau is fixed at 0% specific [3H]‐JNJ‐46281222 binding. (E) Specific [3H]‐JNJ‐46281222 binding after 9 min of dissociation in the absence or presence of GTP. *P <0.05 versus control, determined using Student's two‐tailed unpaired t‐test. All graphs are shown as mean ± SEM of three to six individual experiments performed in duplicate. Where bars are not shown, SEM values are within the symbol.
Figure 4
Figure 4
Saturation binding of radioligands to mGlu2 receptors expressed at CHO‐K1 membranes. (A) Saturation binding of [3H]‐JNJ‐46281222 to the mGlu2 allosteric binding site in the absence or presence of glutamate. (B) Saturation binding of [3H]‐DCG‐IV to the mGlu2 orthosteric binding site, determined by ‘spiked’ saturation (see text). (C) Saturation binding of [3H]‐LY341495 to the orthosteric binding site. Graphs shown are from a representative experiment performed in duplicate in each case.
Figure 5
Figure 5
Characterization of potency of JNJ‐46281222. (A) Stimulation of [35S]‐GTPγS binding to mGlu2 receptors induced by increasing concentrations of JNJ‐46281222. A representative experiment is shown, with similar data obtained in a second experiment. (B) Dose–response curve of JNJ‐46281222 in the presence of glutamate (EC20, 4 μM) on the binding of [35S]‐GTPγS. Data are expressed as the percentage of maximal response induced by 1 mM glutamate and are shown as mean ± SEM of 13 individual experiments performed in triplicate. Where bars are not shown, SEM values are within the symbol.
Figure 6
Figure 6
Molecular dynamics (MD) simulations of the binding of JNJ‐46281222 to the mGlu2 receptor. (A) The complete system used for MD simulations, including mGlu2 receptor 7TM monomer, G protein, ligand (JNJ‐46281222, magenta), lipids and solvent. (B) Close up of 7TM binding site showing interaction with a subset of important amino acids. MD starting position for ligand is coloured magenta; snapshot after 200 ns is turquoise. Movement of W7736.48a.50c from outwards orientation (magenta) at start of simulation to inwards orientation (turquoise) is highlighted. (C) RMSD of mGlu2 receptor monomer during the simulation.
Figure 7
Figure 7
(A) Radioligand binding to mGlu2 receptor mutants F6433.36a.40c and N7355.47a.47c. Specific [3H]‐JNJ‐46281222 binding to WT or mutant mGlu2 receptors, transiently transfected in CHO‐K1 cells. Data were normalized to % specific binding compared with binding to WT mGlu2 receptors and are expressed as mean ± SEM of three individual experiments performed in duplicate. (B) Representative immunoblot of WT (left panel) and mutant mGlu2 receptors (middle, F643, and right, N735, panel) and actin. *P‐value <0.05 compared with WT, analysis was carried out using unnormalized data and determined using one‐way repeated‐measures ANOVA with Dunnett's post test.

Similar articles

Cited by

References

    1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein‐coupled receptors. Br. J. Pharmacol. 170: 1459–1581. - PMC - PubMed
    1. Ball M, Boyd A, Churchill G, Cuthbert M, Drew M, Fielding M, et al (2012). Isoindolone formation via intramolecular Diels–Alder reaction. Org. Process Res. Dev. 16: 741–747.
    1. Berger O, Edholm O, Jähnig F (1997). Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. Biophys. J. 72: 2002–2013. - PMC - PubMed
    1. Cartmell J, Adam G, Chaboz S, Henningsen R, Kemp JA, Klingelschmidt A, et al (1998). Characterization of [3H]‐(2S,2′R,3′R)‐2‐(2′,3′‐dicarboxy‐cyclopropyl)glycine ([3H]‐DCG IV) binding to metabotropic mGlu2 receptor‐transfected cell membranes. Br. J. Pharmacol. 123: 497–504. - PMC - PubMed
    1. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099–3108. - PubMed

Publication types

Substances

LinkOut - more resources